NCT06417892View on ClinicalTrials.gov

Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma

RecruitingOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

April 15, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

December 30, 2026

Conditions
Gastric Cancer
Interventions
DRUG

PD-1inhibitor

PD-1 antibody was selected according to first-line drug use

DRUG

Fruquintinib

a small molecular anti-tumor angiogensis drug

DRUG

albumin paclitaxel

a kind of cytotoxic chemotherapy drug

Trial Locations (1)

100021

RECRUITING

Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER